Literature DB >> 16842397

General practitioners' ranking of evidence-based prescribing quality indicators: a comparative study with a prescription database.

Ifeanyi Okechukwu1, Kathleen Bennett, John Feely.   

Abstract

BACKGROUND: To ensure that indicators for assessing prescribing quality are appropriate and relevant, physicians should be involved in their development. How general practitioners (GPs) rank these indicators is not fully understood. AIMS: (i) To determine how GPs in Ireland rank a set of evidence-based prescribing quality indicators in order of importance and relevance to their practice, and (ii) to compare the GPs' ranking of the defined set of indicators with actual prescribing practice using a prescription database.
METHODS: A postal questionnaire was sent to 105 GPs, who were asked to rank a set of 11 prescribing quality indicators, identified from the literature from most to least important. The results were aggregated and a weighted score for each indicator determined. These same prescribing indicators were then applied to a prescription database to compare the ranking provided with actual prescribing practice.
RESULTS: Eighty-six GPs (82%) returned the completed questionnaire. The higher ranks were for quality issues-use of inhaled corticosteroids, statins and benzodiazepines. Actual prescribing data showed prolonged use of benzodiazepines in over half of the prescriptions dispensed (n = 18 171), 52.48% (95% confidence interval 51.95, 53.01) and low usage of generic drugs, 17.78% (17.70, 17.90) despite their high ranking by the GPs.
CONCLUSION: While GPs have diverse views about the value of different prescribing quality indicators, the results suggest that they do rank evidence-based guidelines on patient management highly, but those based on costs and less evidence the lowest. There was considerable divergence between theory and practice in the application of quality indices.

Entities:  

Mesh:

Year:  2006        PMID: 16842397      PMCID: PMC1885100          DOI: 10.1111/j.1365-2125.2006.02621.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  23 in total

1.  Generic prescribing: time to regulate the market? Price rises are a blow to nascent primary care groups.

Authors:  T Walley; P Burrill
Journal:  BMJ       Date:  2000-01-15

2.  Guidelines for the diagnosis and treatment of chronic heart failure.

Authors:  W J Remme; K Swedberg
Journal:  Eur Heart J       Date:  2001-09       Impact factor: 29.983

3.  Secondary prevention of coronary heart disease in the elderly (with emphasis on patients > or =75 years of age): an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention.

Authors:  Mark A Williams; Jerome L Fleg; Philip A Ades; Bernard R Chaitman; Nancy Houston Miller; Syed M Mohiuddin; Ira S Ockene; C Barr Taylor; Nanette K Wenger
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

4.  The high cost of medicines in Ireland. Is it time to change the pricing mechanism?

Authors:  Lesley Tilson; Bernadette McGowan; Kathleen Bennett; Michael Barry
Journal:  Eur J Health Econ       Date:  2004-12

5.  Prescribing of oral nutritional supplements in Primary Care: can guidelines supported by education improve prescribing practice?

Authors:  M J Gall; J E Harmer; H J Wanstall
Journal:  Clin Nutr       Date:  2001-12       Impact factor: 7.324

6.  Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem.

Authors:  J Page; D Henry
Journal:  Arch Intern Med       Date:  2000-03-27

7.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

Authors: 
Journal:  BMJ       Date:  2002-01-12

8.  ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology.

Authors:  V Fuster; L E Rydén; R W Asinger; D S Cannom; H J Crijns; R L Frye; J L Halperin; G N Kay; W W Klein; S Lévy; R L McNamara; E N Prystowsky; L S Wann; D G Wyse; R J Gibbons; E M Antman; J S Alpert; D P Faxon; V Fuster; G Gregoratos; L F Hiratzka; A K Jacobs; R O Russell; S C Smith; W W Klein; A Alonso-Garcia; C Blomström-Lundqvist; G De Backer; M Flather; J Hradec; A Oto; A Parkhomenko; S Silber; A Torbicki
Journal:  J Am Coll Cardiol       Date:  2001-10       Impact factor: 24.094

9.  Preventing drug-related morbidity--determining valid indicators.

Authors:  C J Morris; J A Cantrill; C D Hepler; P R Noyce
Journal:  Int J Qual Health Care       Date:  2002-06       Impact factor: 2.038

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more
  7 in total

1.  Risk perception in drug therapy.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2006-08       Impact factor: 4.335

2.  Inappropriate medication use and prescribing indicators in elderly Australians: development of a prescribing indicators tool.

Authors:  Benjamin J Basger; Timothy F Chen; Rebekah J Moles
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

3.  Compliance with quality prescribing indicators in terms of their relationship to financial incentives.

Authors:  Rocío Fernández Urrusuno; Ma Carmen Montero Balosa; Pastora Pérez Pérez; Beatriz Pascual de la Pisa
Journal:  Eur J Clin Pharmacol       Date:  2013-06-07       Impact factor: 2.953

4.  Identifying how age and gender influence prescription drug use in a primary health care environment in Catalonia, Spain.

Authors:  Eladio Fernández-Liz; Pilar Modamio; Arantxa Catalán; Cecilia F Lastra; Teresa Rodríguez; Eduardo L Mariño
Journal:  Br J Clin Pharmacol       Date:  2007-10-08       Impact factor: 4.335

5.  A pilot qualitative study to explore stakeholder opinions regarding prescribing quality indicators.

Authors:  Liana Martirosyan; Joekie Markhorst; Petra Denig; Flora M Haaijer-Ruskamp; Jozé Braspenning
Journal:  BMC Health Serv Res       Date:  2012-07-07       Impact factor: 2.655

6.  Identifying potential prescribing safety indicators related to mental health disorders and medications: A systematic review.

Authors:  Wael Y Khawagi; Douglas T Steinke; Joanne Nguyen; Richard N Keers
Journal:  PLoS One       Date:  2019-05-24       Impact factor: 3.240

Review 7.  A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study.

Authors:  Suzanne Dunne; Bill Shannon; Colum Dunne; Walter Cullen
Journal:  BMC Pharmacol Toxicol       Date:  2013-01-05       Impact factor: 2.483

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.